Posted by Michael Wonder on 23 Nov 2022
CSL lands world first gene therapy with $5.3 million haemophilia treatment
23 November 2022 - Australian biotech giant CSL will bring the first gene therapy for haemophilia B to market in the United States after gaining regulatory approval for a new drug called Hemgenix.
CSL confirmed on Wednesday that the US FDA has granted approval for the therapy, which it has been developing since inking a deal worth $US655 million with US biotech UniQure back in 2020.
